Free public records show China Immunotech (Beijing) Biotechnology Co., Ltd. in 5 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by China Immunotech (Beijing) Biotechnology Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
7 active studies led by China Immunotech (Beijing) Biotechnology Co., Ltd., of 9 in all
Source: ClinicalTrials.gov, Studies with China Immunotech (Beijing) Biotechnology Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies China Immunotech (Beijing) Biotechnology Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with China Immunotech (Beijing) Biotechnology Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show China Immunotech (Beijing) Biotechnology Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets China Immunotech (Beijing) Biotechnology Co., Ltd. is in.
Stories on the topics China Immunotech (Beijing) Biotechnology Co., Ltd. works in.
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
Vitamin D is made in sunlight, yet low levels are common even in sunny countries. How much you need, and when…
ReadSearch all reports for China Immunotech (Beijing) Biotechnology Co., Ltd. All companies